The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Two years out of date and counting.
DId I say 201 phase 2 trials were completed? If you are so worried about the peer review maybe look at Astrazeneca.
I invested based on the potential to get the compounds moving making it far more valuable and hopefully with a few deals. Not based on the finished product.
We are a better investment than any other biotech because raising 20/30/40 million in this market for clinical trials probably means a delisting. The lack of risk vs reward should see Val being one of the few that actually does very well. A 2 million cash burn is next to nothing compared to others to be fair as long as they can show some value.
Https://www.telegraph.co.uk/business/2023/10/31/ftse-100-markets-news-mortgages-latest/
30th November 2020 (almost 3 and a half years ago) on the full results from 201 - 'Additional detailed analysis of the results will form the basis of peer-reviewed journal publications.'
You're the enthusiast, I'm the potential investor. Where is the 'additional detailed analysis? Where are the peer reviews? You say 201 is some sort of transformational game changer, I think it's a dead duck. Convince me otherwise, because for now you just look like a soot-juggling ramper trying to pump this to reduce losses.
We are not at that stage of peer reviews. We don't do clinical trials and have not completed a preclinical project yet. Nothing to conclude but potential is strong based on what is out in the public.
https://www.valirx.com/cytolytix-limited
https://www.dundee.ac.uk/stories/new-method-discovered-halt-active-cancer-cells
Compound from Imperial needs no introduction as to how good that would be.
Other than 201, we are investing in the hope that one of these compounds can get a large preclinical deal. Clearly all these show enough promise to indicate they will get through the early stages.
'The science work.....has been really good.'
Can you give me a summary of scientific progress over the last 24 months, preferably with links to RNSs and peer reviews?
Well changes have been made. I never stated everyone should be removed but would have been in favour of a change with a shareholder on the BOD. I just don't see how widespread changes can make anything better or make it faster. It slows it down as we can all see now.
All that matters is outcomes. Even though I am significantly down I think that is more down to a lack of commercial skills on the BOD but I guess that is the reason why the action group picked Adrian otherwise why bother because he has no real experience in this work. The science work and control of finances has actually been really good and the foundations are strong.
PM, I recall you stated that you would give it until the end of March before deciding to give up on any chance that 201 would be progressed.
To be fair to you, I don't recall you stating March of which year, so perhaps you meant March of 2025.
'Val does not do clinical trials.'
True PM. Does Val do anything at all these days?
Shareholders are in favour of it. Large II base. Clueless.
I should probably be a bit clearer, for those narrow-minded of us, whom are unable to grasp my point...............a sign of things to come for AIM.
Val does not do clinical trials so cash burn is not 10s of millions plus hopefully things improve by next year.
Even more important to see 201 over the line and to get some revenue in.
RedX delisting from AIM. Maybe a sign of things to come.
Getting back to VAL.....from RNS dated 15th December 2023:
'CLX001 was placed in the single asset subsidiary company, Cytolytix Limited ("Cytolytix") in Q4 2022, and has undergone a programme of formulation development during H1 2023. The peptide active ingredient requires a nanoformulation to ensure that the peptide stabilised within the therapeutic agent and is delivered to cancer cells at appropriate levels.
The formulation development remains challenging, with further formulations being proposed and undergoing testing during the quarter.'
If they are making progress inline with their expectations, we should have some news on the successful formulation of CLX shortly. The lab is doing f*ck all else to generate any income and this is closest to being sold; So I would expect this activity to top of the 'urgent' pile.
It's dead Jim....
It's all been too quiet recently so maybe we'll get some news this week ..
PJ
Im sick and tired about hearing we might have something worth licensing or selling in 12 to 18 months its always jam tomorrow with this lot but tomorrow never comes.
Generally, for a small biotech, I think having a lab to do their own discovery and pre-clinical work is a good idea.
It saves time and money.
However, Val never seem to publish their work, making it available to a much wider scientific audience.
They never attend conferences and present their work. That in itself seems suspicious to me.
It makes you think that they have nothing of any worth to publish or present. Alternatively, they haven't got what it takes to develop , present and publish to gain the attention of big pharma.
It also explains why only the likes of THX and Ambrose show any interest in Val's products.
Khelder,
This is not a lab business. To outsource the evaluation projects costs money and to improve the chances of success the lab and collaborations help. Also pre clinical testing can be very expensive if outsourced. Much of the cost is offset against the cost of running the lab. Eventually the lab should add more value once they get a deal for one of the pre-clinical projects.
As I said success will depend on how long cash lasts before they can get a deal and getting 201 over the line would really help extend that whilst giving us a higher share price should a bit be needed from a placing in the future. If not then maybe success with CLX news/deal in the next year if possible giving a higher share price or a deal.
At least one of these projects will attract a very large deal in the next 12-18 months. If we are comfortable with cash in the medium term then the company will have a huge upward turn.
Spot on Kheldar....and we've paid a excessive price for something we didn't ask for....As far as Im concerned l expected the 'legacy treatments' to be delivering added value.... sod the Lab and as I've mentioned before, trust in this gang of Director/chancers.. has gone...and if Suzy and her hench men want to dump us and fold valirx to pick up her labs and contracts on the cheap...they will regret the day they try it....not bothering to check post
A lot of hypothesis and a slight absence of facts from you PM.
'... if they use the money wisely..'
'... If the merger completes'
....hopefully
......maybe
.... If the cash runway allows....
.....if we have 401/201 signed
......avoiding a large dilution. (Yet another one, you mean)
Not a ramp (Thanks for making that clear, many will have thought otherwise)
... It simply needs one or two events to happen (Some of which are already three years late, but at least we cut out one hour this morning)
PM2020,
Listen to what you are saying? IF they use the money wisely?. How do they do that?. IF they can't understand that you shouldn't be granted Bonuses If your Co Isn't producing Positive results. Furthermore no matter who grants you those bonuses the CEO should have the Intellect without It being pointed out to her. That she as CEO and staff should Reject Not accept them. AIMO.
PM2022 - I don’t blame any of your posts for my investment here. I made the decisin to invest in the back of CLX. Personally I had no confidence in 201 and still don’t. 3 years and still nothing is really telling. Look back at how Suzy described these drugs as legacy products should tell you what she thinks of them.
Let’s move in from 201 as Suzy has.
My annoyance stems from the pivot had done to becoming a lab business. If I had know that she was going down this route i would never have invested.
Atb
A Gold Award is better than a Raspberry:
PM2022
Posted in: VAL
Posts: 2,825
Price: 42.00
Strong Buy
RE: Breaking 40p28 Dec 2021 10:18
Finally the big week has arrived and it's the final week of the year. Deal due to be announced over the next three days.
40p and a very low market cap of only 27 million. Not much downside once the deal comes this week from here and it would be nice if we finished this year at 70-80p. I think 401 or 301 deal will be announced in early 2022 as well.
https://www.lse.co.uk/profiles/pm2022/?page=100
What happened to that deal 'due to be announced over the next three days'? Some might say that seeing the value of their investment collapse by over 90% since your post above that they have indeed suffered from a 'life changing opportunity' to lose most of their money invested here.
And, is your 'genuine view with the products we have' based on anything other than what you have read other posters post?
Well done. It sounds like you want a gold medal.
This is more of a life changing opportunity. They got cash until early 2025 if they use the money wisely.
If the merger completes and 201 gets signed that extends the cash runway hopefully until the end of 2025 maybe 2026 along with some lab revenue.
Lab revenue will then price in the lab asset. You then got CLX and 4 in the evaluation stage with 2 being truly world class with a high chance of success. If the cash runway allows one early deal for one of these projects and if we have 401/201 signed we will be a 50/100 million market company and that before any dilution. I think 201 being signed even after the delays is essential so that it allows more time to get an early deal or to allow a decent amount of cash to be raised at a higher market cap and avoiding a large dilution.
A 4 Million market cap can very easily move to 50/100 million here even before another dilution. Not a ramp genuine view with the products we have. It simply needs one or two events to happen to change it all here which is still likely in my view.
I did try and warn y’all:
TheBasher
Posted in: VAL
Posts: 714
Price: 5.00
No Opinion
RE: Scientific Advisory Board31 Jan 2024 04:12
@year1970
I completely agree. My post from 2nd Jan 24:
Posted in: VAL
Posts: 677
Price: 5.90
No Opinion
RE: THE YEAR OF THE PHOENIX ?
2 Jan 2024 00:44
Aka THE YEAR OF THE LEPER…
I’ve been in VAL for many years and still hold some shares to show it’s catastrophic loss in my portfolio - it serves as a clear and daily reminder to me not to repeat mistakes of the past.
On 16th Dec, the sp was 14p, and there were keyboard warriors claiming significant funds were coming in and that 20p, 30p, 40p and 50p or more was extremely likely. The sp is now at 5.9p. Says it all really and potential new investors should take note.
Below is what was posted by me 5 Nov 2023 and then on 16th Dec 2023 in response to all the bullish rumours on this board.:
TheBasher
Posted in: VAL
Posts: 651
Price: 14.125
No Opinion
Only 97% down. Tumbleweed moment with VAL 401!
I feel like I’ve been here before…
Oh, I have.
Time will tell if it’s any different to the 2nd, 3rd or however many false starts there have been.
Only need another 900%+ to recover my losses.
A leopard never changes its spots, neither does a leper (which is a pretty apt way of describing a chronically sick excuse of a pharma company).